Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 65

1.

Physiological and transcriptional response of Candida parapsilosis to exogenous tyrosol.

Jakab Á, Tóth Z, Nagy F, Nemes D, Bácskay I, Kardos G, Emri T, Pócsi I, Majoros L, Kovács R.

Appl Environ Microbiol. 2019 Aug 9. pii: AEM.01388-19. doi: 10.1128/AEM.01388-19. [Epub ahead of print]

PMID:
31399405
2.

Synergistic effect of nikkomycin Z with caspofungin and micafungin against Candida albicans and Candida parapsilosis biofilms.

Kovács R, Nagy F, Tóth Z, Bozó A, Balázs B, Majoros L.

Lett Appl Microbiol. 2019 Oct;69(4):271-278. doi: 10.1111/lam.13204. Epub 2019 Aug 23.

PMID:
31385615
3.

Efficacy of humanized single large doses of caspofungin on the lethality and fungal tissue burden in a deeply neutropenic murine model against Candida albicans and Candida dubliniensis.

Prépost E, Tóth Z, Perlin DS, Gesztelyi R, Kardos G, Kovács R, Nagy F, Forgács L, Majoros L.

Infect Drug Resist. 2019 Jul 1;12:1805-1814. doi: 10.2147/IDR.S198764. eCollection 2019.

4.

Farnesol increases the activity of echinocandins against Candida auris biofilms.

Nagy F, Tóth Z, Daróczi L, Székely A, Borman AM, Majoros L, Kovács R.

Med Mycol. 2019 May 25. pii: myz057. doi: 10.1093/mmy/myz057. [Epub ahead of print]

PMID:
31127836
5.

Utilization of vector autoregressive and linear transfer models to follow up the antibiotic resistance spiral in Gram-negative bacteria from cephalosporin consumption to colistin resistance.

Tóth H, Fésus A, Kungler-Gorácz O, Balázs B, Majoros L, Szarka K, Kardos G.

Clin Infect Dis. 2018 Dec 18. doi: 10.1093/cid/ciy1086. [Epub ahead of print]

PMID:
30561543
6.

In Vivo Applicability of Neosartorya fischeri Antifungal Protein 2 (NFAP2) in Treatment of Vulvovaginal Candidiasis.

Kovács R, Holzknecht J, Hargitai Z, Papp C, Farkas A, Borics A, Tóth L, Váradi G, Tóth GK, Kovács I, Dubrac S, Majoros L, Marx F, Galgóczy L.

Antimicrob Agents Chemother. 2019 Jan 29;63(2). pii: e01777-18. doi: 10.1128/AAC.01777-18. Print 2019 Feb.

7.

Comparison of Killing Activity of Micafungin Against Six Candida Species Isolated from Peritoneal and Pleural Cavities in RPMI-1640, 10 and 30% Serum.

Tóth Z, Kardos T, Kovács R, Kardos G, Nagy F, Prépost E, Barta Z, Takacs I, Majoros L.

Mycopathologia. 2018 Dec;183(6):905-912. doi: 10.1007/s11046-018-0302-5. Epub 2018 Oct 31.

PMID:
30382508
8.

Fluconazole is not inferior than caspofungin, micafungin or amphotericin B in the presence of 50% human serum against Candida albicans and Candida parapsilosis biofilms.

Nagy F, Tóth Z, Bozó A, Czeglédi A, Rebenku I, Majoros L, Kovács R.

Med Mycol. 2018 Oct 18. doi: 10.1093/mmy/myy108. [Epub ahead of print]

PMID:
30339227
9.

Poor in vivo efficacy of caspofungin, micafungin and amphotericin B against wild-type Candida krusei clinical isolates does not correlate with in vitro susceptibility results.

Kardos T, Kovács R, Kardos G, Varga I, Bozó A, Tóth Z, Nagy F, Majoros L.

J Chemother. 2018 Jul;30(4):233-239. doi: 10.1080/1120009X.2018.1487150. Epub 2018 Jul 20.

PMID:
30025501
10.

Postantifungal effect of micafungin against Candida albicans, Candida dubliniensis and Candida africana in the presence and absence of serum.

Kardos T, Saleh Q, Kovács R, Gesztelyi R, Kardos G, Bozó A, Tóth Z, Majoros L.

New Microbiol. 2017 Oct;40(4):286-288. Epub 2017 Oct 10.

11.

In vitro antifungal susceptibility patterns of planktonic and sessile Candida kefyr clinical isolates.

Nagy F, Bozó A, Tóth Z, Daróczi L, Majoros L, Kovács R.

Med Mycol. 2018 Jun 1;56(4):493-500. doi: 10.1093/mmy/myx062.

PMID:
28992253
12.

Candida albicans isolates from a single hospital show low phenotypical specialization.

Boros E, Pfliegler WP, Kovács R, Jakab Á, Majoros L, Barta Z, Pócsi I.

J Basic Microbiol. 2017 Nov;57(11):910-921. doi: 10.1002/jobm.201700037. Epub 2017 Sep 11.

PMID:
28891112
13.

Commercial strain-derived clinical Saccharomyces cerevisiae can evolve new phenotypes without higher pathogenicity.

Pfliegler WP, Boros E, Pázmándi K, Jakab Á, Zsuga I, Kovács R, Urbán E, Antunovics Z, Bácsi A, Sipiczki M, Majoros L, Pócsi I.

Mol Nutr Food Res. 2017 Nov;61(11). doi: 10.1002/mnfr.201601099. Epub 2017 Aug 29.

PMID:
28731263
14.

Killing Activity of Micafungin Against Candida albicans, C. dubliniensis and Candida africana in the Presence of Human Serum.

Kovács R, Saleh Q, Bozó A, Tóth Z, Gesztelyi R, Kardos T, Kardos G, Takacs I, Majoros L.

Mycopathologia. 2017 Dec;182(11-12):979-987. doi: 10.1007/s11046-017-0178-9. Epub 2017 Jul 11.

PMID:
28699056
15.

Activity of exogenous tyrosol in combination with caspofungin and micafungin against Candida parapsilosis sessile cells.

Kovács R, Tóth Z, Nagy F, Daróczi L, Bozó A, Majoros L.

J Appl Microbiol. 2017 Jun;122(6):1529-1536. doi: 10.1111/jam.13452. Epub 2017 May 3.

PMID:
28321957
16.

Addressing Analytical Challenges of the Environmental Monitoring for the Water Framework Directive: ERM-CE100, a New Biota Certified Reference Material.

Dosis I, Ricci M, Majoros L, Lava R, Emteborg H, Held A, Emons H.

Anal Chem. 2017 Feb 21;89(4):2514-2521. doi: 10.1021/acs.analchem.6b04682. Epub 2017 Feb 3.

17.

Decreased Killing Activity of Micafungin Against Candida guilliermondii, Candida lusitaniae, and Candida kefyr in the Presence of Human Serum.

Saleh Q, Kovács R, Kardos G, Gesztelyi R, Kardos T, Bozó A, Majoros L.

Microb Drug Resist. 2017 Sep;23(6):764-770. doi: 10.1089/mdr.2016.0241. Epub 2017 Jan 10.

PMID:
28072553
18.

Effects of hemin, CO2, and pH on the branching of Candida albicans filamentous forms.

Jakab Á, Antal K, Emri T, Boczonádi I, Imre A, Gebri E, Majoros L, Pfliegler WP, Szarka M, Balla G, Balla J, Pócsi I.

Acta Microbiol Immunol Hung. 2016 Dec;63(4):387-403. doi: 10.1556/030.63.2016.023. Epub 2016 Dec 12.

PMID:
27936861
19.

The in vitro and in vivo efficacy of fluconazole in combination with farnesol against Candida albicans isolates using a murine vulvovaginitis model.

Bozó A, Domán M, Majoros L, Kardos G, Varga I, Kovács R.

J Microbiol. 2016 Nov;54(11):753-760. Epub 2016 Oct 29.

PMID:
27796932
20.

Killing Rates of Caspofungin in 50 Percent Serum Correlate with Caspofungin Efficacy Against Candida albicans in a Neutropenic Murine Model.

Domán M, Kovács R, Kardos G, Gesztelyi R, Juhász B, Bozó A, Kardos T, Saleh Q, Majoros L.

Curr Drug Deliv. 2016;13(2):255-64.

PMID:
27146910
21.

Asymptomatic faecal carriage of ESBL producing enterobacteriaceae in Hungarian healthy individuals and in long-term care applicants: A shift towards CTX-M producers in the community.

Ebrahimi F, Mózes J, Mészáros J, Juhász Á, Majoros L, Szarka K, Kardos G.

Infect Dis (Lond). 2016 Jul;48(7):557-9. doi: 10.3109/23744235.2016.1155734. Epub 2016 Mar 16.

PMID:
26982242
22.

Effect of caspofungin and micafungin in combination with farnesol against Candida parapsilosis biofilms.

Kovács R, Bozó A, Gesztelyi R, Domán M, Kardos G, Nagy F, Tóth Z, Majoros L.

Int J Antimicrob Agents. 2016 Apr;47(4):304-10. doi: 10.1016/j.ijantimicag.2016.01.007. Epub 2016 Feb 17.

PMID:
26968084
23.

Comparison of rates of fecal colonization with extended-spectrum beta-lactamase-producing enterobacteria among patients in different wards, outpatients and medical students.

Ebrahimi F, Mózes J, Monostori J, Gorácz O, Fésűs A, Majoros L, Szarka K, Kardos G.

Microbiol Immunol. 2016 May;60(5):285-94. doi: 10.1111/1348-0421.12373.

24.

Dose escalation studies with caspofungin against Candida glabrata.

Domán M, Kovács R, Perlin DS, Kardos G, Gesztelyi R, Juhász B, Bozó A, Majoros L.

J Med Microbiol. 2015 Sep;64(9):998-1007. doi: 10.1099/jmm.0.000116. Epub 2015 Jun 30.

25.

Betamethasone augments the antifungal effect of menadione--towards a novel anti-Candida albicans combination therapy.

Jakab Á, Emri T, Sipos L, Kiss Á, Kovács R, Dombrádi V, Kemény-Beke Á, Balla J, Majoros L, Pócsi I.

J Basic Microbiol. 2015 Aug;55(8):973-81. doi: 10.1002/jobm.201400903. Epub 2015 Feb 24.

PMID:
25707543
26.

Efficacy of single large doses of caspofungin in a neutropenic murine model against the "psilosis" group.

Berényi R, Kovács R, Domán M, Gesztelyi R, Kardos G, Juhász B, Perlin D, Majoros L.

New Microbiol. 2014 Jul;37(3):355-62. Epub 2014 Jul 1.

27.

Killing rates for caspofungin against Candida albicans after brief and continuous caspofungin exposure in the presence and absence of serum.

Kovács R, Gesztelyi R, Perlin DS, Kardos G, Domán M, Berényi R, Majoros L.

Mycopathologia. 2014 Oct;178(3-4):197-206. doi: 10.1007/s11046-014-9799-4. Epub 2014 Aug 15.

PMID:
25118874
28.

Serum interleukin-6 levels in murine models of Candida albicans infection.

Kovács R, Czudar A, Horváth L, Szakács L, Majoros L, Kónya J.

Acta Microbiol Immunol Hung. 2014 Mar;61(1):61-9. doi: 10.1556/AMicr.61.2014.1.6.

PMID:
24631754
29.

Studies on the possible aetiological role of different Candida species in pathogenesis of dentine caries by monitoring the calcium release from tooth particles.

Szabó B, Majoros L, Papp-Falusi E, Szabó Z, Szabó J, Márton I, Kelentey B.

Acta Microbiol Immunol Hung. 2014 Mar;61(1):11-7. doi: 10.1556/AMicr.61.2014.1.2.

PMID:
24631750
30.

Killing rates exerted by caspofungin in 50 % serum and its correlation with in vivo efficacy in a neutropenic murine model against Candida krusei and Candida inconspicua.

Kovács R, Gesztelyi R, Berényi R, Domán M, Kardos G, Juhász B, Majoros L.

J Med Microbiol. 2014 Feb;63(Pt 2):186-94. doi: 10.1099/jmm.0.066381-0. Epub 2013 Nov 1.

PMID:
24184471
31.

A potential role of aminoglycoside resistance in endemic occurrence of Pseudomonas aeruginosa strains in lower airways of mechanically ventilated patients.

Mózes J, Szűcs I, Molnár D, Jakab P, Fatemeh E, Szilasi M, Majoros L, Orosi P, Kardos G.

Diagn Microbiol Infect Dis. 2014 Jan;78(1):79-84. doi: 10.1016/j.diagmicrobio.2013.09.015. Epub 2013 Oct 7.

PMID:
24183948
32.

Full method validation for the determination of hexachlorobenzene and hexachlorobutadiene in fish tissue by GC-IDMS.

Majoros LI, Lava R, Ricci M, Binici B, Sandor F, Held A, Emons H.

Talanta. 2013 Nov 15;116:251-8. doi: 10.1016/j.talanta.2013.04.080. Epub 2013 May 14.

PMID:
24148401
33.

Echinocandins: production and applications.

Emri T, Majoros L, Tóth V, Pócsi I.

Appl Microbiol Biotechnol. 2013 Apr;97(8):3267-84. doi: 10.1007/s00253-013-4761-9. Epub 2013 Mar 6. Review.

PMID:
23463246
34.

Effect of 50% human serum on the killing activity of micafungin against eight Candida species using time-kill methodology.

Földi R, Szilágyi J, Kardos G, Berényi R, Kovács R, Majoros L.

Diagn Microbiol Infect Dis. 2012 Aug;73(4):338-42. doi: 10.1016/j.diagmicrobio.2012.05.011. Epub 2012 Jun 20.

PMID:
22726529
35.

Comparison of the kidney fungal burden in experimental disseminated candidiasis by species of the Candida parapsilosis complex treated with fluconazole, amphotericin B and caspofungin in a temporarily neutropenic murine model.

Szilágyi J, Földi R, Gesztelyi R, Bayegan S, Kardos G, Juhász B, Majoros L.

Chemotherapy. 2012;58(2):159-64. doi: 10.1159/000337088. Epub 2012 May 24.

PMID:
22626860
36.

Fusion of the Fc part of human IgG1 to CD14 enhances its binding to gram-negative bacteria and mediates phagocytosis by Fc receptors of neutrophils.

Vida A, Bardoel B, Milder F, Majoros L, Sümegi A, Bácsi A, Vereb G, van Kessel KP, van Strijp JA, Antal-Szalmás P.

Immunol Lett. 2012 Aug 30;146(1-2):31-9. doi: 10.1016/j.imlet.2012.04.008. Epub 2012 May 2.

PMID:
22575527
37.

Comparison of in vitro and vivo efficacy of caspofungin against Candida parapsilosis, C. orthopsilosis, C. metapsilosis and C. albicans.

Földi R, Kovács R, Gesztelyi R, Kardos G, Berényi R, Juhász B, Szilágyi J, Mózes J, Majoros L.

Mycopathologia. 2012 Oct;174(4):311-8. doi: 10.1007/s11046-012-9554-7. Epub 2012 May 8.

PMID:
22565489
38.

Effect of nikkomycin Z and 50% human serum on the killing activity of high-concentration caspofungin against Candida species using time-kill methodology.

Szilágyi J, Földi R, Bayegan S, Kardos G, Majoros L.

J Chemother. 2012 Feb;24(1):18-25. doi: 10.1179/1120009X12Z.0000000005.

PMID:
22546720
39.

Protein phosphatase CaPpz1 is involved in cation homeostasis, cell wall integrity and virulence of Candida albicans.

Adám C, Erdei E, Casado C, Kovács L, González A, Majoros L, Petrényi K, Bagossi P, Farkas I, Molnar M, Pócsi I, Ariño J, Dombrádi V.

Microbiology. 2012 May;158(Pt 5):1258-67. doi: 10.1099/mic.0.057075-0. Epub 2012 Feb 16.

PMID:
22343349
40.

Efficacy of a single 6 mg/kg versus two 3 mg/kg caspofungin doses for treatment of disseminated candidiasis caused by Candida albicans in a neutropenic mouse model.

Bayegan S, Szilágyi J, Kemény-Beke Á, Földi R, Kardos G, Gesztelyi R, Juhasz B, Adnan A, Majoros L.

J Chemother. 2011 Apr;23(2):107-9.

PMID:
21571628
41.

Effect of asymmetry of concentration-response curves on the results obtained by the receptorial responsiveness method (RRM): an in silico study.

Grenczer M, Zsuga J, Majoros L, Pinter A, Kemeny-Beke A, Juhasz B, Tosaki A, Gesztelyi R.

Can J Physiol Pharmacol. 2010 Nov;88(11):1074-83. doi: 10.1139/y10-089.

PMID:
21076495
42.

Genotypic and phenotypic properties of Candida parapsilosis sensu strictu strains isolated from different geographic regions and body sites.

Tavanti A, Hensgens LA, Mogavero S, Majoros L, Senesi S, Campa M.

BMC Microbiol. 2010 Jul 28;10:203. doi: 10.1186/1471-2180-10-203.

43.

The polymorphism of protein phosphatase Z1 gene in Candida albicans.

Kovács L, Farkas I, Majoros L, Miskei M, Pócsi I, Dombrádi V.

J Basic Microbiol. 2010 Dec;50 Suppl 1:S74-82. doi: 10.1002/jobm.200900434.

PMID:
20473966
44.

In vivo studies with a Candida tropicalis isolate exhibiting paradoxical growth in vitro in the presence of high concentration of caspofungin.

Bayegan S, Majoros L, Kardos G, Kemény-Beke A, Miszti C, Kovacs R, Gesztelyi R.

J Microbiol. 2010 Apr;48(2):170-3. doi: 10.1007/s12275-010-9221-y. Epub 2010 May 1.

PMID:
20437148
45.

In vitro efficacy of amphotericin B, 5-fluorocytosine, fluconazole, voriconazole and posaconazole against Candida dubliniensis isolates using time-kill methodology.

Szabo Z, Borbely A, Kardos G, Somogyvari F, Kemény-Beke A, Asztalos L, Rozgonyi F, Majoros L.

Mycoses. 2010 May;53(3):196-9. doi: 10.1111/j.1439-0507.2009.01705.x. Epub 2009 Sep 16.

PMID:
19761489
46.

In vitro efficacy of 5 antifungal agents against Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis as determined by time-kill methodology.

Szabó Z, Szilágyi J, Tavanti A, Kardos G, Rozgonyi F, Bayegan S, Majoros L.

Diagn Microbiol Infect Dis. 2009 Jul;64(3):283-8. doi: 10.1016/j.diagmicrobio.2009.03.011. Epub 2009 Apr 25.

PMID:
19394787
47.

Difference in killing activity of caspofungin and paradoxical growth between Candida albicans and C. krusei clinical isolates in different media.

Varga I, Sóczó G, Kardos G, Kemény-Beke A, Kelentey B, Márton I, Majoros L.

J Chemother. 2009 Feb;21(1):36-41.

PMID:
19297270
48.

Comparison of killing activity of caspofungin against Candida parapsilosis, Candida orthopsilosis and Candida metapsilosis.

Varga I, Sóczó G, Kardos G, Borbély A, Szabó Z, Kemény-Beke A, Majoros L.

J Antimicrob Chemother. 2008 Dec;62(6):1466-8. doi: 10.1093/jac/dkn403. Epub 2008 Sep 28. No abstract available.

PMID:
18824459
49.

Physiological and morphological characterization of tert -butylhydroperoxide tolerant Candida albicans mutants.

Fekete A, Pócsi I, Emri T, Gyetvai A, Gazdag Z, Pesti M, Karányi Z, Majoros L, Gergely L, Pócsi I.

J Basic Microbiol. 2008 Dec;48(6):480-7. doi: 10.1002/jobm.200800114.

PMID:
18785661
50.

Time-kill studies investigating the killing activity of caspofungin against Candida dubliniensis: comparing RPMI-1640 and antibiotic medium 3.

Varga I, Sóczó G, Kardos G, Majoros L.

J Antimicrob Chemother. 2008 Jul;62(1):149-52. doi: 10.1093/jac/dkn144. Epub 2008 Apr 4.

PMID:
18390882

Supplemental Content

Loading ...
Support Center